June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
3 citations
,
January 2025 in “SAGE Open Medical Case Reports” Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
7 citations
,
March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.
6 citations
,
October 2021 in “Brain Sciences” Dutasteride may help reduce brain inflammation and improve cognition.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.
December 2025 in “Fertility and Sterility” Both LNG-IUD and systemic progestins are effective for fertility-sparing treatment, but close monitoring is needed due to recurrence risk.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
1 citations
,
May 2025 in “The Journal of Rheumatology” Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
37 citations
,
December 2001 in “Journal of the American Academy of Dermatology” Thalidomide significantly improved hair regrowth in a woman with lichen planopilaris.
12 citations
,
June 2024 in “JAAD Case Reports” Tirzepatide may improve hair loss by reducing insulin resistance.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
1 citations
,
November 2023 in “Journal of neurology” A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
16 citations
,
August 2011 in “Annals of Allergy Asthma & Immunology” A woman with severe angioedema improved significantly after treatment with rituximab.
5 citations
,
July 2023 in “International Journal of Women’s Dermatology” Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
November 2025 in “DOAJ (DOAJ: Directory of Open Access Journals)” The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
April 2026 in “Clinical Journal of Gastroenterology” Upadacitinib can cause hypersensitivity that worsens ulcerative colitis symptoms.
10 citations
,
January 2000 in “PubMed” Both finasteride and GnRH agonist treatments reduced hair growth in women with idiopathic hirsutism, but GnRH agonist was more effective.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
November 2025 in “Journal of Diabetes Investigation” Dapagliflozin improved blood sugar control in a man with Werner syndrome without side effects.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Rituximab can cause skin issues, but baricitinib may help improve them.